290
Participants
Start Date
June 30, 2016
Primary Completion Date
December 30, 2025
Study Completion Date
December 31, 2025
X-396 (ensartinib)
oral ALK inhibitor
crizotinib
oral ALK inhibitor
Border Medical Oncology Research Unit, Albury
Catholic University of Louvain (UCL) - Site Mont Godinne, Yvoir
Charite Campus Virchow-Klinikum, Berlin
Azienda Socio Sanitaria Territoriale (ASST) della Valtellina e dell'Alto Laria, Sondrio
IEO Istituto Europeo di Oncologia, Milan
Trakya University Balkan Oncology Hospital, Edirne
Lungen Clinic Grosshansdorf, Großhansdorf
University Cancer & Blood Center, Athens
Moffitt Cancer Center, Tampa
Hopital Arnaud de Villeneuve, Montpellier
CHU de Rennes Hôpital Pontchaillou, Rennes
Krajská zdravotní, a.s., Masarykova nemocnice, Ústí nad Labem
Rabin Medical Center Institute of Oncology, Davidoff Center, Petah Tikva
CHRU Lille, Lille
Washington University School of Medicine, St Louis
Vítkovická Nemocnice , a.s., Ostrava-Vitkovice
Providence Portland Medical Center, Portland
Beijing Chao Yang Hospital, Beijing
Peking Union Medical College Hospital, Beijing
Peking University Cancer Hospital, Beijing
Peking University Cancer Hospital, Beijing
Beijing Chest Hospital,Capital Medical University, Beijing
The First Hospital of China Medical University, Shenyang
Federal State Budgetary Scientific Institution Russian Oncological Scientific Center named after N.N. Blokhin, Moscow
"LLC Vitamed", Moscow
The First Bethune Hospital of Jilin University, Changchun
Jilin Cancer Hospital, Changchun
Moscow City Oncology Hospital #63, Moscow
Pavlov First Medical University, Saint Petersburg
Shanghai Chest Hospital, Shanghai
Nanjing General Hospital, Nanjing
Anhui Provincial Hospital, Hefei
The Affiliated Hospital of Qingdao University, Qingdao
Zhejiang Cancer Hospital, Hangzhou
Fujian Provincial Cancer Hospital, Fuzhou
Hunan Cancer Hospital, Changsha
Union Hospital of Tongji Medical College of Huazhong Science and Techology University, Wuhan
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan
Hubei Cancer Hospital, Wuhan
Guangdong General Hospital, Guangzhou
Hadassah Medical Center, Jerusalem
Sanatorio Parque S.A., Rosario
Chris O'Brien Lifehouse, Camperdown
Chris O Brien Lifehouse, Camperdown
Fundacao do ABC Faculdade de Medicina do ABC, São Paulo
Zhejiang Cancer Hospital, Hangzhou
Hopital Saint-Louis, Vellefaux
Prince of Wales Hospital, Hong Kong
Queen Elizabeth Hospital, Hong Kong
The University of Hong Kong/Queen Mary Hospital, Hong Kong
Prince of Wales Hospital, Shatin
Medical University of Gdansk, Gdansk
"BIH of Omsk Region Clinical Oncology Dispensary", Omsk
Petrov Research Institute of Oncology, Saint Petersburg
Instituto do Câncer do Estado de São Paulo, São Paulo
Hospital de Câncer de Barretos - Fundação Pio XII, São Paulo
Hospital Haroldo Juaçaba - Instituto do Cancêr do Ceará, Fortaleza
Infirmière recherche Clinique, IUCPQ, Québec
Fourth Hospital of Hebei Medical University, Shijiazhuang
Centro Operativo Studi Clinici S.C.Oncologia Medica, Perugia
VU Medical Center, Amsterdam
Maastricht University Medical Centre (MUMC), Maastricht
Seoul National University Hospital, Seoul
Asan Medical Center, Seoul
Hospital del Mar, Barcelona
Hospital de la Santa Creu i Sant Pau, Barcelona
Hospital Vall d'Hebrón, Barcelona
Hospital Son Ltatzer, Palma de Mallorca
Blackpool Victoria Hospital, Blackwood
Southmead Hospital, Bristol
The Clatterbridge Cancer Centre NHS Foundation Trust, Metropolitan Borough of Wirral
Kings Mill Hospital, Nottingham
Xcovery Holdings, Inc.
INDUSTRY